RxDoctor Payments Data

Samantha Coates, APRN

Family · Dunedin, FLNPI 1508529959

Payments from drug & device makers

$2,380in general payments, 2019–2025

Across 73 payments — averaging $32.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$675
  • AbbVie$441
  • Novo Nordisk$401
  • Lilly USA, LLC$281
  • AstraZeneca$197
  • Inspire Medical Systems, Inc.$68
  • plus $319 from 10 others

What the payments were for

  • Food & beverage$2,380100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,380 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$85,977
Medicare patients
505
Services billed
1,279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$30,063
FarxigaDapagliflozin Propanediol12$17,339
MounjaroTirzepatide13$11,974
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,981
PaxlovidNirmatrelvir/Ritonavir19$1,367
Escitalopram Oxalate48$955
Atorvastatin Calcium101$925
Rosuvastatin Calcium62$874
Albuterol Sulfate HfaAlbuterol Sulfate32$756
Losartan Potassium75$711
Azelastine Hcl34$685
Buspirone Hcl28$600
Levothyroxine Sodium58$597
Methylprednisolone73$566
Amlodipine Besylate66$475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$401$30,06328 claims
AstraZenecaFarxiga$197$17,33912 claims
Lilly USA, LLCMounjaro$281$11,97413 claims
GSKTrelegy Ellipta$675$6,98111 claims
PfizerPaxlovid$48$1,36719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.

Other family in Dunedin

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →